Furthermore, as we show that SAA production and bone loss are dependent on inflammatory cytokines, the clinical relevance of SAA proteins as a biomarker of bone loss may be extended to other pathologies such as chronic cardiovascular diseases (79, 80), inflammatory rheumatic diseases as well as COVID-19 (81), in which the systemic levels of SAA are elevated. This evidence concerns the gene SAA2 and COVID-19.